Luboš Tuček

Luboš Tuček

Auto-generated profile, based on publicly available information

Luboš Tuček

Department of Dentistry, Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2013 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
PCPetr Celakovsky
Petr Celakovsky
DKDavid Kalfert
David Kalfert
LTLubos Tucek
Lubos Tucek
JMJan Mejzli­k
Jan Mejzli­k
MKMilos Kotulek
Milos Kotulek
APAdam Pasz
Adam Pasz

31 July 2015 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
JLJan Laco
Jan Laco
KSKateřina Sieglová
Kateřina Sieglová
HVHana Vošmiková
Hana Vošmiková
PDPavel Dundr
Pavel Dundr
KNKristyna Nemejcova
Kristyna Nemejcova
ARAleš Ryška
Aleš Ryška

19 May 2015 in Australian Dental Journal
Verified
Journal Article
Closed access
PDF file
PCP Celakovsky
P Celakovsky
DKDavid Kalfert
David Kalfert
KSK Smatanova
K Smatanova
LTL Tucek
L Tucek
EČEva Čermáková
Eva Čermáková
THT Hoskova
T Hoskova

11 January 2011 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
JLJan Laco
Jan Laco
HVHana Vosmikova
Hana Vosmikova
VNVendula Novakova
Vendula Novakova
PCPetr Celakovsky
Petr Celakovsky
HDHelena Dolezalova
Helena Dolezalova
ARAleš Ryška
Aleš Ryška


1 January 2012 in Neoplasma
Verified
Journal Article
Closed access
JLJan Laco
Jan Laco
JNJana Nekvindova
Jana Nekvindova
VNV. Novakova
V. Novakova
PCP. Celakovsky
P. Celakovsky
HDH. Dolezalova
H. Dolezalova
ARAleš Ryška
Aleš Ryška
The aim of this study is to evaluate the biologic importance and prognostic significance of selected clinicopathological parameters in patients with oral (OSCC) and oropharyngeal (OPSCC) squamous cell carcinoma, with emphasis on smoking, protein p16(INK4a) (p16) expression, and human papillomavirus (HPV) status.The study sample consisted of 48 patients with OSCC and 44 patients with OPSCC. Half of the patients were nonsmokers and the other half were gender-, age- and tumor localization-matched smokers. p16 expression was detected in 17/48 (35 %) OSCCs and in 36/44 (82 %) OPSCCs and HPV DNA was present in 7/48 (15 %) OSCCs and in 35/44 (80 %) OPSCCs. The sensitivity and specificity of p16 expression for HPV DNA presence were 0.74 and 0.88, respectively. The OPSCCs were more frequently basaloid (p < 0.001) while the OSCCs were more frequently conventional (p < 0.000001). The OSCCs were more likely to recur locally and to be the cause of death (p = 0.009 in both parameters).The HPV-positive tumors were more frequently localized in oropharynx, were basaloid SCCs and were p16- and HPV-positive (p < 0.000001 in all 4 parameters). The HPV-negative tumors were more frequently localized in oral cavity (p < 0.000001), more frequently asociated with local, regional and locoregional recurence (p = 0.011, p = 0.019 and p = 0.030, respectively) and with tumor-related death (p = 0.003). There was no significant difference with regard to smoking history (p > 0.05). The survival of patients with HPV-positive tumors was significantly longer (median 112 months; 95% CI 54 - 112 months) than that of patients with HPV-negative tumors (median 17 months; 95% CI 12 - 39 months) (p < 0.001). The HPV status of OSCC/OPSCC is an important biological and prognostic parameter and should be examined in all cases, using PCR or immunohistochemical detection of surrogate marker p16. Smoking itself does not seem to be an important prognostic factor.